



PRESS RELEASE

For immediate publication

Damae Medical Celebrates Milestone: 1st Patient Enrolled in Landmark French Health-Economic Study

Paris, France – 2 April, 2024 - Damae Medical, developer of innovative imaging devices and artificial intelligence solutions that provide unmatched diagnostic support to dermatologists, proudly announces the recruitment of the first patient in a groundbreaking health-economic study in dermatological imaging, financed by the French government as part of the France 2030 program. This pivotal moment marks a significant step forward in advancing the diagnosis and management of skin conditions, particularly for basal cell carcinoma (BCC).

BCC, the most prevalent form of cancer, poses a significant public health threat worldwide with a current incidence of 4.3 million cases per year. Standard diagnostic practices, including biopsy, can lead to potentially painful and unnecessary invasive procedures as well as long wait times to obtain confirmation of diagnosis. Recognizing the issue, Damae Medical developed the innovative deepLive™ solution, a CE-marked Class IIa technology capable of diagnosing BCC with a superior precision of more than 15 points as compared to traditional clinical and dermoscopic methods. Consequently avoiding unnecessary biopsies, ensuring personalization of patient care and, when possible, an immediate start of non-invasive treatments.

deepLive™ has already demonstrated clinical efficacy and achieved clinical adoption in 14 countries worldwide. However, the path to widespread clinical integration necessitates not only clinical but also economic proof of its superiority over existing standards. In 2023, Damae initiated this proof, after discussions with the Haute Autorité de Santé (HAS), a French independent, scientific public authority, aiming to develop quality in the healthcare field.

[The ECOBASO study](#) is the first French randomized trial designed to evaluate the health-economic impact of deepLive™ diagnostics on BCC management compared to traditional invasive biopsy procedures. With more than 700 patients set to be enrolled across 10 investigating centers in France, including 5 public hospitals and 5 private practices, the ECOBASO study represents a comprehensive effort to revolutionize dermatological care in France. By leveraging deepLive™ technology, the study seeks to reduce the number of invasive procedures, optimize resource utilization and ultimately reduce the total cost of BCC case management after one year, without compromising cure rates.

The enrollment of the first patient in the ECOBASO study is just the start of showcasing the feasibility and potential of integrating deepLive™ into routine clinical practice. Professor Philippe Saiag, consultant in dermatology and venerology at Ambroise-Paré Hospital (AP-HP) in Boulogne-Billancourt and primary investigator of the study, emphasizes, *“I am convinced*

that deepLive™ can replace invasive biopsies in the management of BCCs, thus granting patients improved access to non-invasive diagnostic techniques while simultaneously reducing monetary, time, and labor expenditures.”

The French National Syndicate of Dermatologists and Venereologists (SNDV) echoes this sentiment, highlighting the urgent need for more efficient and cost-effective care amidst a growing shortage of dermatological resources in France. The Syndicate President, Dr. Luc Sulimovic, affirms, *“The implementation of deepLive™ offers a transformative solution to improve and standardize diagnostics in particular amongst dermatologists working in private offices who are on the frontline of BCC management. The ECOBASO study endeavors to promote the adoption of this technology by private and public dermatologists alike, with the ultimate goal of enhancing patient care pathways across all French territories, which is perfectly in line with SNDV’s initiatives around Specialized Dermatology-Venereology Care Teams (Équipes de Soins Spécialisés - ESS).”*

Anaïs Barut, President and Co-Founder of Damae Medical, marks the commencement of the study, stating, *“At Damae Medical, we are all grateful to the patients and healthcare professionals involved in the ECOBASO study. They contribute enormously to our efforts to extend access to our transformative technology to as many people as possible. We are confident that the results of the ECOBASO study will lead to the rapid creation of reimbursement in France - the only obstacle preventing patients from benefiting from deepLive™ examinations today.”*

The results of the ECOBASO study, expected in 2026, hold the promise of reshaping dermatological practice and improving outcomes for patients across France and beyond.

List of the 10 investigating centers for the ECOBASO study:

Public Hospitals

- Hôpital Ambroise Paré (AP-HP, Boulogne-Billancourt): **Prof. Philippe Saiag** (Principal Investigator), Dr. Elisa Funck-Brentano, Dr. Leire Lara-Gonzalez and Dr. Romain Samaran.
- Hôpital Saint-Louis (AP-HP, Paris): Dr. Barouyr Baroudjian and Dr. Emilien Ezine
- Hôpital Edouard Herriot (HCL, Lyon): Dr. Marie Danset
- CHU de Saint-Etienne: Prof. Jean-Luc Perrot
- Hôpital de l'Archet (CHU, Nice): Prof. Philippe Bahadoran and Dr. Florence Le Duff

Private Clinic Centers

- Dr. Hervé Garat – Centre d'Imagerie en Dermatologie (CID), Marseille
 - Dr. Marina Thomas – Clinique privée de l'Yvette, Longjumeau
 - Dr. Fabrice Ribeau and Dr. Elise Cesbron – Centre Médical République, Le Mans
 - Dr. Hugues Cartier, Dr. Cyril Maire and Dr. Clémence Gros – Centre Saint-Jean, Arras
 - Dr. Nathalie Lalanne and Dr. Aurélia Gey-Valiergue – Cabinet Gambetta, Bordeaux
-

For media inquiries, thank you for contacting:

Anja Kleber – VP Sales & Marketing

+33 (0)6 07 95 44 39

anja@damae-medical.com

www.damae-medical.com